FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Provenge | Dendreon

Dendreon tripling workforce ahead of expected vax launch


Over the years Seattle-based Dendreon made a global name for itself as it developed one of the world's first therapeutic vaccines. It's also advanced the careers of scores of biotech executives who have gone on to a wide variety of other drug developers.

"Anybody who can sustain through what Dendreon has sustained--it's a good sign of who they are," Martin Simonetti, the former chief financial officer at Dendreon and now CEO of Seattle-based VLST, tells Xconomy's Luke Timmerman. "You really had a lot of entrepreneurial risk-takers there. There were a lot of good people that made good things happen."

Timmerman carefully tracked down the whereabouts of a long lineup of Dendreon alumni. And Dendreon is promising to help jazz the Seattle biotech scene with plenty of new development veterans. The company tells Xconomy that its workforce, 200 a year ago, is growing to 600 this year as it prepares for a highly-anticipated regulatory decision on Provenge.

- check out the Xconomy story to see where Dendreon veterans have landed

Related Articles:
Dendreon files Provenge BLA
Dendreon jumps on 'heavyweight' board appointments
Dendreon shares gyrate on Provenge panel rumor
Dendreon upbeat on ability to make Provenge next year

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about Provenge   Dendreon  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.